Zacks Investment Research on MSN
PRPO vs. NEO: Which cancer diagnostics stock is the better buy?
Specialty oncology diagnostics companies continue to operate in a dynamic healthcare environment, driven by advances in ...
StockStory.org on MSN
NeoGenomics (NEO) stock trades up, here is why
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.4% in the afternoon session ...
Rare Earth Stock Neo (TSX: NEO) Makes TSX Top Gainer List on Increased 2026 Adjusted EBITDA Guidance
Neo Performance Materials (TSX: NEO) raises 2026 Adjusted EBITDA guidance to $140-150 million on strong critical materials ...
Throughout its cycle, NEO has aligned closely with the Adhishthana Principles, our proprietary model that blends behavioral archetypes with quantitative signals. One of the best examples of this was ...
NEOGENOMICS ($NEO) posted quarterly earnings results on Tuesday, February 18th. The company reported earnings of $0.04 per share, beating estimates of $0.03 by $0.01 ...
Assessing recent share performance Neo Performance Materials (TSX:NEO) has attracted fresh interest after a strong run in the stock, with returns of 4.7% over the past day and 8.5% over the past week.
Neo Performance Materials is a rare-earth pick focused on processing and magnet production—the real supply-chain bottleneck.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results